AR130114A1 - Agonistas de receptores muscarínicos - Google Patents
Agonistas de receptores muscarínicosInfo
- Publication number
- AR130114A1 AR130114A1 ARP230102050A ARP230102050A AR130114A1 AR 130114 A1 AR130114 A1 AR 130114A1 AR P230102050 A ARP230102050 A AR P230102050A AR P230102050 A ARP230102050 A AR P230102050A AR 130114 A1 AR130114 A1 AR 130114A1
- Authority
- AR
- Argentina
- Prior art keywords
- salts
- compounds
- treatment
- compound
- crystalline forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta invención se refiere a compuestos y sales de los mismos que son agonistas de receptores muscarínicos, útiles en el tratamiento de enfermedades mediadas por receptores muscarínicos. También se proporcionan formas cristalinas de los compuestos y sales de los mismos; composiciones farmacéuticas que contienen los compuestos y sales de los mismos, o formas cristalinas de los mismos; usos terapéuticos de los compuestos y sales de los mismos, o formas cristalinas de los mismos; métodos de síntesis de los mismos; e intermediarios útiles en dichos métodos de síntesis. Reivindicación 1: Un compuesto de fórmula (1); o una sal del mismo. Reivindicación 3: Una sal de adición de ácido de un compuesto de acuerdo con la reivindicación 1. Reivindicación 4: La sal de adición de ácido de acuerdo con la reivindicación 3, en donde el ácido se selecciona de: 2,5-dihidroxibenzoico (gentísico), 2-furoico, acético, butandioico (succínico), cítrico, etansulfónico (ESA), fumárico, glucónico (D), glucurónico (D), hidroxiacético (glicólico), clorhídrico (HCl), maleico, málico (L), malónico, N-acetilglicina (acetúrico), nicotínico, ortofosfórico (fosfórico), oxoglutárico (cetoglutárico), p-toluensulfónico (p-TSA), piroglutámico (L) y sulfúrico y tartárico (L). Reivindicación 6: Una sal de citrato de un compuesto de acuerdo con la reivindicación 1. Reivindicación 7: Una sal de citrato monohidrato de un compuesto de acuerdo con la reivindicación 1. Reivindicación 11: El compuesto o la composición de acuerdo con cualquiera de las reivindicaciones 1 a 9 para usar en el tratamiento de un trastorno cognitivo o trastorno psicótico, o para el tratamiento o la disminución de la gravedad del dolor agudo, crónico, neuropático o inflamatorio.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2211399.7A GB202211399D0 (en) | 2022-08-04 | 2022-08-04 | Muscarinic receptor agonists |
| GBGB2305444.8A GB202305444D0 (en) | 2023-04-13 | 2023-04-13 | Muscarinic receptor agonists |
| GBGB2309615.9A GB202309615D0 (en) | 2023-06-26 | 2023-06-26 | Muscarinic receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130114A1 true AR130114A1 (es) | 2024-11-06 |
Family
ID=87696205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102050A AR130114A1 (es) | 2022-08-04 | 2023-08-03 | Agonistas de receptores muscarínicos |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20250340531A1 (es) |
| EP (2) | EP4508045B1 (es) |
| JP (1) | JP2025526601A (es) |
| KR (1) | KR20250041066A (es) |
| CN (1) | CN119866336A (es) |
| AR (1) | AR130114A1 (es) |
| AU (1) | AU2023317835A1 (es) |
| CA (1) | CA3263797A1 (es) |
| CL (1) | CL2025000299A1 (es) |
| CO (1) | CO2025002413A2 (es) |
| CR (1) | CR20250069A (es) |
| DK (1) | DK4508045T3 (es) |
| DO (1) | DOP2025000015A (es) |
| ES (1) | ES3050097T3 (es) |
| FI (1) | FI4508045T3 (es) |
| HR (1) | HRP20251427T1 (es) |
| IL (1) | IL318739A (es) |
| LT (1) | LT4508045T (es) |
| MA (1) | MA69856B1 (es) |
| MX (1) | MX2025001312A (es) |
| PE (1) | PE20251236A1 (es) |
| PT (1) | PT4508045T (es) |
| RS (1) | RS67422B1 (es) |
| SI (1) | SI4508045T1 (es) |
| TW (1) | TW202416955A (es) |
| WO (1) | WO2024028458A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025030095A1 (en) * | 2023-08-03 | 2025-02-06 | Neurocrine Biosciences, Inc. | Methods of synthesis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2015008203A0 (en) * | 2012-08-10 | 2015-01-31 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (BTK) inhibitors |
| RS57843B1 (sr) | 2014-02-06 | 2018-12-31 | Heptares Therapeutics Ltd | Biciklična aza jedinjenja kao agonisti muskarinskog receptora m1 |
-
2023
- 2023-08-03 AR ARP230102050A patent/AR130114A1/es unknown
- 2023-08-03 WO PCT/EP2023/071591 patent/WO2024028458A2/en not_active Ceased
- 2023-08-03 FI FIEP23757194.8T patent/FI4508045T3/fi active
- 2023-08-03 SI SI202330050T patent/SI4508045T1/sl unknown
- 2023-08-03 TW TW112129182A patent/TW202416955A/zh unknown
- 2023-08-03 CR CR20250069A patent/CR20250069A/es unknown
- 2023-08-03 ES ES23757194T patent/ES3050097T3/es active Active
- 2023-08-03 HR HRP20251427TT patent/HRP20251427T1/hr unknown
- 2023-08-03 LT LTEPPCT/EP2023/071591T patent/LT4508045T/lt unknown
- 2023-08-03 AU AU2023317835A patent/AU2023317835A1/en active Pending
- 2023-08-03 EP EP23757194.8A patent/EP4508045B1/en active Active
- 2023-08-03 PE PE2025000295A patent/PE20251236A1/es unknown
- 2023-08-03 CA CA3263797A patent/CA3263797A1/en active Pending
- 2023-08-03 DK DK23757194.8T patent/DK4508045T3/da active
- 2023-08-03 CN CN202380057529.4A patent/CN119866336A/zh active Pending
- 2023-08-03 EP EP25198643.6A patent/EP4663190A2/en active Pending
- 2023-08-03 KR KR1020257006895A patent/KR20250041066A/ko active Pending
- 2023-08-03 IL IL318739A patent/IL318739A/en unknown
- 2023-08-03 PT PT237571948T patent/PT4508045T/pt unknown
- 2023-08-03 JP JP2025505853A patent/JP2025526601A/ja active Pending
- 2023-08-03 US US18/867,575 patent/US20250340531A1/en active Pending
- 2023-08-03 RS RS20251164A patent/RS67422B1/sr unknown
- 2023-08-03 MA MA69856A patent/MA69856B1/fr unknown
-
2025
- 2025-01-31 DO DO2025000015A patent/DOP2025000015A/es unknown
- 2025-01-31 MX MX2025001312A patent/MX2025001312A/es unknown
- 2025-01-31 CL CL2025000299A patent/CL2025000299A1/es unknown
- 2025-02-28 CO CONC2025/0002413A patent/CO2025002413A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20251236A1 (es) | 2025-04-29 |
| MA69856B1 (fr) | 2025-10-31 |
| WO2024028458A2 (en) | 2024-02-08 |
| DOP2025000015A (es) | 2025-04-08 |
| WO2024028458A3 (en) | 2024-03-21 |
| MX2025001312A (es) | 2025-05-02 |
| LT4508045T (lt) | 2025-11-25 |
| DK4508045T3 (da) | 2025-10-20 |
| HRP20251427T1 (hr) | 2025-12-19 |
| ES3050097T3 (en) | 2025-12-19 |
| CN119866336A (zh) | 2025-04-22 |
| TW202416955A (zh) | 2024-05-01 |
| SI4508045T1 (sl) | 2025-11-28 |
| RS67422B1 (sr) | 2025-12-31 |
| EP4508045B1 (en) | 2025-10-01 |
| IL318739A (en) | 2025-03-01 |
| AU2023317835A1 (en) | 2025-03-20 |
| CL2025000299A1 (es) | 2025-08-08 |
| PT4508045T (pt) | 2025-10-29 |
| FI4508045T3 (fi) | 2025-11-13 |
| CA3263797A1 (en) | 2024-02-08 |
| EP4508045A2 (en) | 2025-02-19 |
| JP2025526601A (ja) | 2025-08-15 |
| CR20250069A (es) | 2025-05-26 |
| US20250340531A1 (en) | 2025-11-06 |
| EP4663190A2 (en) | 2025-12-17 |
| CO2025002413A2 (es) | 2025-06-16 |
| KR20250041066A (ko) | 2025-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2564454T3 (es) | Compuesto de piperazina que puede inhibir la prostaglandina D sintasa | |
| ECSP034563A (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos | |
| JP5813855B2 (ja) | Ｌｓｄ１阻害剤としてのシクロプロピルアミン | |
| RU2569303C2 (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| AR130114A1 (es) | Agonistas de receptores muscarínicos | |
| JPH06506227A (ja) | ５α−リダクターゼ阻害剤および抗アンドロゲン剤を含む前立腺過形成を治療するための併用薬剤組成物 | |
| AU2006344987B8 (en) | Enantiomerically pure flavone derivatives for the treatment of proliferative disorders and processes for their preparation | |
| TW202246265A (zh) | 一種選擇性parp1抑制劑及其應用 | |
| NZ540449A (en) | Novel compounds having selective inhibiting effect at GSK3 | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| WO2013040528A1 (en) | Antimicrobial compounds | |
| SK17252002A3 (sk) | Deriváty acylfenylmočoviny, spôsoby ich výroby a použitie ako liečivo | |
| CZ312694A3 (en) | Derivatives of oxazolidin-2-one, process of their preparation and pharmaceutical compositions based thereon | |
| CR20230485A (es) | Derivados de fósforo como nuevos inhibidores de sos1 | |
| CA3147571A1 (en) | Nlrp3 modulators | |
| PE20191103A1 (es) | Inhibidores de dopamina-b-hidroxilasa | |
| AR121544A1 (es) | Inhibidores de la vía de señalización por cbp / catenina y sus usos | |
| CO2023001367A2 (es) | Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterocíclicos farmacológicamente activos | |
| US20080176947A1 (en) | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors | |
| WO2009092284A1 (zh) | 苯并环庚烯类衍生物、其制备方法及医药用途 | |
| MX2025008207A (es) | Estereoisomero y derivado deuterado de compuesto de pirazoloquinazolina y uso | |
| EP1594853B1 (de) | Verfahren zur herstellung bicyclischer aromatischer aminosäuren sowie deren zwischenprodukte | |
| ECSP24032316A (es) | Derivados de amina bicíclicos como moduladores de receptor gabaa alfa 5 | |
| JP6349303B2 (ja) | 細菌性疾患の処置のためのピリミジン誘導体 | |
| IL292900A (en) | Nitrogen oxide-donating pde-5 and/or pde-6 inhibitor compounds |